



# TumorPlus 263

## Broad-Spectrum Support for Cancer Cell Culture

From immortalized cancer models to patient-derived cell lines, tumor cell culture demands flexible, robust media capable of supporting high proliferation and consistent phenotype. TumorPlus 263 is a ready-to-use solution developed to meet these challenges across a wide range of adherent and suspension tumor cell lines.

Its optimized formulation promotes cell viability and growth in diverse oncology workflows — from drug screening and target validation to biomarker discovery and assay development. Whether you work with epithelial, hematopoietic, or neuroblastoma models, TumorPlus 263 offers the reliability and ease-of-use your protocols need.

### KEY BENEFITS OF TumorPlus 263

#### » Ready-to-Use Format

Simply open the bottle and get started: TumorPlus 263 comes fully supplemented, saving time and making workflows more consistent

#### » Broad Cell Line Compatibility

Supports robust growth of a wide range of tumor-derived cell lines without previous adaptation — including adherent and suspension types

#### » With Pre-Selected Serum Components


Includes high-quality serum with consistently low endotoxin levels to promote reliable growth and minimize biological variability

#### » Trusted for Diverse Applications

Ideal for proliferation assays, drug screening, and long-term culture of established or primary tumor cell lines

## VALIDATED ACROSS DIVERSE TUMOR CELL LINES

Tumor cell models vary widely in their origin, growth behavior, and metabolic demands – yet TumorPlus 263 consistently supports robust viability across a range of cell types. To assess its performance, six commonly used tumor cell lines were cultured in TumorPlus 263 and compared to standard media.



**Fig. 1 Cells were seeded in reference media and in TumorPlus 263 and cultivated for 72 hours.** Viability was quantified using a Resazurin-based metabolic activity assay, and viability was calculated as the ratio of signal intensity in TumorPlus 263 and reference medium. Results are based on four independent experiments per cell line. Reference media: DMEM + 10% FBS (A375, HeLa, Hep2G); RPMI + 10%FBS (A549, Jurkat); McCoy's 5A + 10% FBS (HT-29).

All tested cell lines showed enhanced viability in TumorPlus 263. Particularly strong effects were observed in HeLa, Jurkat, and HepG2 cells. The data demonstrate that TumorPlus 263 supports both adherent and suspension cell types, enabling consistent performance without additional supplementation.

## APPLICATIONS OF TumorPlus 263 - RELIABLE SUPPORT FOR ALL CANCER CELL WORKFLOWS

TumorPlus 263 is suitable for a wide range of applications involving tumor-derived cell lines, including long-term maintenance, proliferation assays, and compound screening. Its balanced formulation supports both established and primary cancer models, in adherent or suspension formats. Whether used for routine culture or more demanding preclinical workflows, TumorPlus 263 offers consistent performance and convenience.

### ORDER INFORMATION

#### PRODUCT

#### TumorPlus 263

Complete Medium for Tumor Cells,  
with L-Glutamine

#### VOL. CAT.NO.

500 ml TP-A



SCAN FOR MORE  
INFORMATION

For further support, feel free to contact our experts at [techservice@capricorn-scientific.com](mailto:techservice@capricorn-scientific.com) or phone (+49 6424 944 64 0).

Capricorn Scientific GmbH  
Auf der Lette 13 A  
35085 Ebsdorfergrund  
Germany

Tel.: +49 6424 944 64 0  
Fax: +49 6424 944 64-20

[info@capricorn-scientific.com](mailto:info@capricorn-scientific.com)  
[www.capricorn-scientific.com](http://www.capricorn-scientific.com)